Pivot Pharma Launches Canadian Cannabis and Nutraceutical Manufacturing Facility

Comment Cannabisradar.info: Pivot is on the home stretch to begin its production activities within the next three months on the new production facility in Quebec. Pivot Pharma Launches Canadian Cannabis and Nutraceutical Manufacturing Facility Health Canada licensing documentation in preparation; production to start in next 90 days VANCOUVER , Nov. 25, 2019 /CNW/ – Pivot

Nabis Holdings Completes Investments in Two Additional Assets in Emmett Township and Kawkawlin, Michigan

November 18, 2019 VANCOUVER, British Columbia, Nov. 18, 2019 (GLOBE NEWSWIRE) — Nabis Holdings Inc. (NAB.CN) (OTC:NABIF) (FRA:A2PL) (“NabisTM” or the “Company”), a leading Canadian investment company with specialty investments in assets across multiple divisions of the cannabis sector, today announced that it has completed its investments in two strategically located properties that have municipal

Nabis Holdings Announces Changes to the Board

November 16, 2019 VANCOUVER, British Columbia, Nov. 15, 2019 (GLOBE NEWSWIRE) — Nabis Holdings Inc. (NAB.CN) (OTC:NABIF) (FRA:A2PL) (“Nabis™” or the “Company”), a leading Canadian investment company with specialty investments in assets across multiple divisions of the cannabis sector, today announced the appointment of Yoni Ashurov, Founder and CEO of MWR Life, to the Company’s

Nabis Holdings Receives Regulatory Approval to Operate its New Assets, Emerald Phoenix and Infusion Edibles in Arizona

Comment Cannabisradar.info: We still like the strong investment portfolio of Nabis Holdings and their big cash position of 20,2 Mio C$ as of July 30,2019! The recent news release confirms our view, that the company is well positioned to benefit from their strategic investments in various US states.   Nabis Holdings Receives Regulatory Approval to

Our Cannabis/-Biotech company gives hope to people suffering from the neuropsychiatric disorder ‘Fragile X Syndrome (FXS)’!

As the second most common chromosomal disorder after Down syndrome, 22q is caused by a small missing piece of the 22nd chromosome. The deletion occurs near the middle of the chromosome at a location designated q11.2. It is considered a mid-line condition, with physical symptoms including characteristic palate abnormalities, heart defects, immune dysfunction, and esophageal